Drugs / ATG-fresenium
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00798785 Background | Oct 2006 → Dec 2014 | type 1 diabetes mellitus | University Hospital Brussels | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-fresenium | “ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.” NCT00798785 ↗ |
| Action | Deplete | “Induction therapy with a T cell-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the most frequently used immune suppression (IS) regimen in islet...” PMID 27779572 ↗ Sep 2017 |